Dr. Peter McCullough

Think about that. It's an unpopular finding. It's disgusting. It is disgusting. I'm sorry. I took you way off course, but there we are. So, by the way, so let me just reframe my thing, speaking of frame shifts, which was I'm prepared to accept this is COVID. Vaccine, COVID plus vaccine. I'm prepared for all of it because guess what? In science, you just take the data as it comes.

Think about that. It's an unpopular finding. It's disgusting. It is disgusting. I'm sorry. I took you way off course, but there we are. So, by the way, so let me just reframe my thing, speaking of frame shifts, which was I'm prepared to accept this is COVID. Vaccine, COVID plus vaccine. I'm prepared for all of it because guess what? In science, you just take the data as it comes.

But you have to ask the question. And your evidence so far, because of the massive duration of the spike in, you know, the Patterson group is finding it in what are called non-classical monocytes. And those non-classical monocytes are intercalating into the central nervous system and not going through their normal cycle of apoptosis.

But you have to ask the question. And your evidence so far, because of the massive duration of the spike in, you know, the Patterson group is finding it in what are called non-classical monocytes. And those non-classical monocytes are intercalating into the central nervous system and not going through their normal cycle of apoptosis.

which they're persisting, causing inflammation and God knows what in the brain. I've done my rant. I'll let you have it now.

which they're persisting, causing inflammation and God knows what in the brain. I've done my rant. I'll let you have it now.

Well-framed, I like the way you described it, vital pharmaceutical data from recent public precisely what they're doing. I wanna address something I just saw on the restream. Somebody is saying, well, why did you vaccinate your elderly patients? I'll tell you why, I would do it again. I vaccinated my elderly patients because they were at serious risk from COVID. You were not.

Well-framed, I like the way you described it, vital pharmaceutical data from recent public precisely what they're doing. I wanna address something I just saw on the restream. Somebody is saying, well, why did you vaccinate your elderly patients? I'll tell you why, I would do it again. I vaccinated my elderly patients because they were at serious risk from COVID. You were not.

My 85 and nine-year-old patients were, and some died. And when I had something to offer them, I looked at the data. Now, mind you, the data was off. I did not know some of the shortfalls of the Pfizer data that perhaps I should have known. I think I still would have used it. And they benefited. They stopped dying. And I saw zero adverse events in the elderly patients.

My 85 and nine-year-old patients were, and some died. And when I had something to offer them, I looked at the data. Now, mind you, the data was off. I did not know some of the shortfalls of the Pfizer data that perhaps I should have known. I think I still would have used it. And they benefited. They stopped dying. And I saw zero adverse events in the elderly patients.

Most of them wanted a booster. I sort of supported that. I didn't recommend it, but I said, okay. But we started getting two and three boosters. What I started telling all my patients was, this is up to you because I'm not recommending it because I have no idea what we're doing. I don't know what we're doing.

Most of them wanted a booster. I sort of supported that. I didn't recommend it, but I said, okay. But we started getting two and three boosters. What I started telling all my patients was, this is up to you because I'm not recommending it because I have no idea what we're doing. I don't know what we're doing.

This is a booster for a pathogen that left the Southern California area where I practiced six months ago. Now, there was all this data. Will it still reduce the seriousness of illness? No, no, I don't buy it. I don't buy it. And at what risk? At what risk? I couldn't tell at what risk yet because they wouldn't give us the data and they still haven't given us that data.

This is a booster for a pathogen that left the Southern California area where I practiced six months ago. Now, there was all this data. Will it still reduce the seriousness of illness? No, no, I don't buy it. I don't buy it. And at what risk? At what risk? I couldn't tell at what risk yet because they wouldn't give us the data and they still haven't given us that data.

So let's see who is asking this of me. Somebody asked me. Was it Dexter? Did you ask the question? Or Maureen? Bro-bruh. Bro-truth. Bro-truth asked me that question. And so it was challenging times. I would still do it again. I would... I don't know if I would have boosted at all. We know now. But I definitely would have given the vaccine.

So let's see who is asking this of me. Somebody asked me. Was it Dexter? Did you ask the question? Or Maureen? Bro-bruh. Bro-truth. Bro-truth asked me that question. And so it was challenging times. I would still do it again. I would... I don't know if I would have boosted at all. We know now. But I definitely would have given the vaccine.

And I actually only... Elderly patients did not seem to be getting as much side effect in my experience. I know Steve... Oh, crap. Help me, Caleb. Steve's last name from Silicon Valley. Steve Kirsch disagrees with me that there was lots of cardiac events in the elderly. I didn't see it. I did see atrial fibrillation in one 100-year-old. Here's my story with that. And this was way down the line.

And I actually only... Elderly patients did not seem to be getting as much side effect in my experience. I know Steve... Oh, crap. Help me, Caleb. Steve's last name from Silicon Valley. Steve Kirsch disagrees with me that there was lots of cardiac events in the elderly. I didn't see it. I did see atrial fibrillation in one 100-year-old. Here's my story with that. And this was way down the line.

And she insisted on multiple boosters. She had rapid ventricular response, atrial fibrillation at home in a nursing home. She was 100. She would not come into the hospital. I had to treat it as an outpatient. Anticoagulation was a major risk for her, which is what you normally do with atrial fibrillation. And thankfully, my skill and luck, she got through it and there was no consequence.

And she insisted on multiple boosters. She had rapid ventricular response, atrial fibrillation at home in a nursing home. She was 100. She would not come into the hospital. I had to treat it as an outpatient. Anticoagulation was a major risk for her, which is what you normally do with atrial fibrillation. And thankfully, my skill and luck, she got through it and there was no consequence.